Diflucan P.O.S.: Formulary list price $1.3654/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3654 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18010 · Verify on the e-Formulary ↗ (DIN 02024152)
Source record
DIN 02024152: Diflucan P.O.S.
Raw flags: sec12=Y, sec3=Y
Item: 081204025; group id 8; item number 0010; lccId 00001; manufacturer id PFI
Source form: O/L; strength: 10mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3654; ministry $1.3654
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02024152
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18010
Shortage status: resolved shortage (ended 2017-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02024152
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Fluconazole · DIN 02281260 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Fluconazole · DIN 02281260
Manufacturer: Actavis Pharma Company; listing date 2008-01-15
Daily cost (source): $2.5808
Health Canada: Marketed since 2020-04-16 · brand ACT FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Teva canada limited · schedule Prescription
Act Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76691 · Verify on the e-Formulary ↗ (DIN 02281260)
Source record
DIN 02281260: Act Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id ACV
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02281260
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76691Interchangeable products
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: discontinued (2024-12-20, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02281260
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Fluconazole · DIN 02237370 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Fluconazole · DIN 02237370
Manufacturer: Apotex Inc.; listing date 1999-09-15
Daily cost (source): $2.5808
Health Canada: Marketed since 2024-08-29 · brand APO-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Apotex inc · schedule Prescription
Apo-Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60693 · Verify on the e-Formulary ↗ (DIN 02237370)
Source record
DIN 02237370: Apo-Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id APX
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237370
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60693Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: shortage reported ended 2026-06-05 (report last updated 2026-06-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237370
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fluconazole · DIN 02517396 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fluconazole · DIN 02517396
Manufacturer: Sanis Health Inc.; listing date 2022-03-31
Daily cost (source): $2.5808
Health Canada: Marketed since 2022-01-14 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Sanis health inc · schedule Prescription
Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100680 · Verify on the e-Formulary ↗ (DIN 02517396)
Source record
DIN 02517396: Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id SAI
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517396
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100680Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02517396
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fluconazole · DIN 02534886 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fluconazole · DIN 02534886
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-12-29
Daily cost (source): $2.5808
Health Canada: Marketed since 2023-10-24 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102377 · Verify on the e-Formulary ↗ (DIN 02534886)
Source record
DIN 02534886: Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id SIV
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534886
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102377Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534886
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Fluconazole · DIN 02245292 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Fluconazole · DIN 02245292
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2003-04-16
Daily cost (source): $2.5808
Health Canada: Marketed since 2010-04-16 · brand MYLAN-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69316 · Verify on the e-Formulary ↗ (DIN 02245292)
Source record
DIN 02245292: Mylan-Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id MYL
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245292
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69316Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245292
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Fluconazole · DIN 02245643 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Fluconazole · DIN 02245643
Manufacturer: Pharmascience Inc.; listing date 2003-01-30
Daily cost (source): $2.5808
Health Canada: Marketed since 2002-06-05 · brand PMS-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Pharmascience inc · schedule Prescription
PMS-Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69743 · Verify on the e-Formulary ↗ (DIN 02245643)
Source record
DIN 02245643: PMS-Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id PMS
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245643
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69743Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: resolved shortage (ended 2019-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245643
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Fluconazole · DIN 02281279 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Fluconazole · DIN 02281279
Manufacturer: Actavis Pharma Company; listing date 2008-01-15
Daily cost (source): $2.2891
Health Canada: Marketed since 2020-04-16 · brand ACT FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Teva canada limited · schedule Prescription
Act Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76692 · Verify on the e-Formulary ↗ (DIN 02281279)
Source record
DIN 02281279: Act Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id ACV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02281279
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76692Interchangeable products
Apo-Fluconazole · DIN 02237371 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02517418 · $2.2891
Fluconazole · DIN 02534894 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: discontinued (2024-12-20, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02281279
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Fluconazole · DIN 02237371 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Fluconazole · DIN 02237371
Manufacturer: Apotex Inc.; listing date 1999-09-15
Daily cost (source): $2.2891
Health Canada: Marketed since 2024-08-29 · brand APO-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Apotex inc · schedule Prescription
Apo-Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60694 · Verify on the e-Formulary ↗ (DIN 02237371)
Source record
DIN 02237371: Apo-Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id APX
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237371
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60694Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02517418 · $2.2891
Fluconazole · DIN 02534894 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: resolved shortage (ended 2022-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237371
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fluconazole · DIN 02517418 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fluconazole · DIN 02517418
Manufacturer: Sanis Health Inc.; listing date 2022-03-31
Daily cost (source): $2.2891
Health Canada: Marketed since 2022-01-14 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Sanis health inc · schedule Prescription
Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100681 · Verify on the e-Formulary ↗ (DIN 02517418)
Source record
DIN 02517418: Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id SAI
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517418
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100681Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Apo-Fluconazole · DIN 02237371 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02534894 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02517418
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fluconazole · DIN 02534894 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fluconazole · DIN 02534894
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-12-29
Daily cost (source): $2.2891
Health Canada: Marketed since 2023-10-24 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102378 · Verify on the e-Formulary ↗ (DIN 02534894)
Source record
DIN 02534894: Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id SIV
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534894
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102378Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Apo-Fluconazole · DIN 02237371 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02517418 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534894
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Fluconazole · DIN 02245293 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Fluconazole · DIN 02245293
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2003-04-16
Daily cost (source): $2.2891
Health Canada: Marketed since 2009-12-17 · brand MYLAN-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69317 · Verify on the e-Formulary ↗ (DIN 02245293)
Source record
DIN 02245293: Mylan-Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id MYL
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245293
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69317Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Apo-Fluconazole · DIN 02237371 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02517418 · $2.2891
Fluconazole · DIN 02534894 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: anticipated shortage (last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245293
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Fluconazole · DIN 02245644 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Fluconazole · DIN 02245644
Manufacturer: Pharmascience Inc.; listing date 2003-01-30
Daily cost (source): $2.2891
Health Canada: Marketed since 2002-06-05 · brand PMS-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Pharmascience inc · schedule Prescription
PMS-Fluconazole: Formulary list price $2.2891/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2891 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69744 · Verify on the e-Formulary ↗ (DIN 02245644)
Source record
DIN 02245644: PMS-Fluconazole
Raw flags: sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id PMS
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $2.2891; ministry $2.2891
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245644
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69744Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Apo-Fluconazole · DIN 02237371 · $2.2891
Diflucan · DIN 00891819 · not recorded
Fluconazole · DIN 02517418 · $2.2891
Fluconazole · DIN 02534894 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: resolved shortage (ended 2019-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245644
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Fluconazole-150 · DIN 02241895 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Fluconazole-150 · DIN 02241895
Manufacturer: Apotex Inc.; listing date 2001-03-07
Health Canada: Marketed since 2011-03-02 · brand APO-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Apotex inc · schedule Non-prescription drugs
Apo-Fluconazole-150: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65565 · Verify on the e-Formulary ↗ (DIN 02241895)
Source record
DIN 02241895: Apo-Fluconazole-150
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id APX
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241895
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65565Interchangeable products
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241895
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diflucan-150 · DIN 02141442 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Diflucan-150 · DIN 02141442
Manufacturer: Pfizer Canada Inc.; listing date 1998-12-31
Health Canada: Marketed since 2019-07-25 · brand DIFLUCAN ONE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Pfizer canada ulc · schedule Non-prescription drugs
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789 · Verify on the e-Formulary ↗ (DIN 02141442)
Source record
DIN 02141442: Diflucan-150
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id PFI
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $15.6500; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02141442
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02141442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fluconazole-150 · DIN 02521229 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Fluconazole-150 · DIN 02521229
Manufacturer: Sanis Health Inc.; listing date 2022-07-29
Health Canada: Marketed since 2022-05-12 · brand FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Sanis health inc · schedule Non-prescription drugs
Fluconazole-150: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101044 · Verify on the e-Formulary ↗ (DIN 02521229)
Source record
DIN 02521229: Fluconazole-150
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id SAI
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521229
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101044Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521229
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Fluconazole 150mg · DIN 02547864 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Fluconazole 150mg · DIN 02547864
Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30
Health Canada: Marketed since 2025-03-11 · brand JAMP FLUCONAZOLE 150 MG · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Jamp Fluconazole 150mg: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103678 · Verify on the e-Formulary ↗ (DIN 02547864)
Source record
DIN 02547864: Jamp Fluconazole 150mg
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id JPC
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547864
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103678Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02547864
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Fluconazole-150 · DIN 02428792 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Fluconazole-150 · DIN 02428792
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2017-01-31
Health Canada: Marketed since 2016-12-14 · brand MAR-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Marcan pharmaceuticals inc · schedule Non-prescription drugs
Mar-Fluconazole-150: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91325 · Verify on the e-Formulary ↗ (DIN 02428792)
Source record
DIN 02428792: Mar-Fluconazole-150
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id MAR
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428792
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91325Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428792
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Priva-Fluconazole · DIN 02433702 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Priva-Fluconazole · DIN 02433702
Manufacturer: Pharmapar Inc.; listing date 2021-06-30
Health Canada: Marketed since 2025-01-17 · brand NRA-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Nora pharma inc · schedule Non-prescription drugs
Priva-Fluconazole: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91806 · Verify on the e-Formulary ↗ (DIN 02433702)
Source record
DIN 02433702: Priva-Fluconazole
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id PHP
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02433702
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91806Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: resolved shortage (ended 2025-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02433702
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Fluconazole · DIN 02255510 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Fluconazole · DIN 02255510
Manufacturer: Laboratoire Riva Inc.; listing date 2024-04-30
Health Canada: Marketed since 2014-11-01 · brand RIVA-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Laboratoire riva inc. · schedule Non-prescription drugs
Riva-Fluconazole: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74071 · Verify on the e-Formulary ↗ (DIN 02255510)
Source record
DIN 02255510: Riva-Fluconazole
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id RIA
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02255510
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74071Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Jamp-Fluconazole · DIN 02432471 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02255510
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Fluconazole · DIN 02432471 · 150mg · capsule
Limited Use — Reason for Use code 235 requiredDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusLimited Use — Reason for Use code 235 required
Write on scriptLU code 235 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 235
Reason for Use code 235
For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.
Coverage limit:
Repeats within a 25 day period will not be reimbursed.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Fluconazole · DIN 02432471
Manufacturer: Jamp Pharma Corporation; listing date 2015-03-31
Health Canada: Dormant since 2026-08-03 · brand JAMP-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Jamp-Fluconazole: Formulary list price $3.9424/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9424 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91671 · Verify on the e-Formulary ↗ (DIN 02432471)
Source record
DIN 02432471: Jamp-Fluconazole
Raw flags: sec12=Y, sec3=Y
Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id JPC
Source form: Cap; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.9424; ministry $3.9424
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432471
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91671Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424
Diflucan-150 · DIN 02141442 · $3.9424
Fluconazole-150 · DIN 02521229 · $3.9424
Jamp Fluconazole 150mg · DIN 02547864 · $3.9424
Mar-Fluconazole-150 · DIN 02428792 · $3.9424
Priva-Fluconazole · DIN 02433702 · $3.9424
Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02432471
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
Teva-Fluconazole · DIN 02236978 · 50mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.Discontinued 2025-07-30 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Fluconazole · DIN 02236978
Manufacturer: Teva Canada Limited; listing date 2003-04-16
Daily cost (source): $2.5808
Health Canada: Cancelled post market since 2025-07-30 · brand TEVA-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Teva canada limited · schedule Prescription
Teva-Fluconazole: Formulary list price $1.2904/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2904 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60273 · Verify on the e-Formulary ↗ (DIN 02236978)
Source record
DIN 02236978: Teva-Fluconazole
Raw flags: sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id TEV
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.2904; ministry $1.2904
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236978
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60273Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Diflucan · DIN 00891800 · not recorded
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02236978
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Diflucan · DIN 00891800 · 50mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.Discontinued 2025-07-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diflucan · DIN 00891800
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Daily cost (source): $2.5808
Health Canada: Cancelled post market since 2025-07-02 · brand DIFLUCAN · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Pfizer canada ulc · schedule Prescription
Diflucan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10952 · Verify on the e-Formulary ↗ (DIN 00891800)
Source record
DIN 00891800: Diflucan
Raw flags: notABenefit=Y, sec3=Y
Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id PFI
Source form: Tab; strength: 50mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00891800
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10952Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904
Apo-Fluconazole · DIN 02237370 · $1.2904
Fluconazole · DIN 02517396 · $1.2904
Fluconazole · DIN 02534886 · $1.2904
Mylan-Fluconazole · DIN 02245292 · $1.2904
PMS-Fluconazole · DIN 02245643 · $1.2904
Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00891800
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Diflucan · DIN 00891819 · 100mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.Discontinued 2025-07-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diflucan · DIN 00891819
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Daily cost (source): $2.2891
Health Canada: Cancelled post market since 2025-07-02 · brand DIFLUCAN · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Pfizer canada ulc · schedule Prescription
Diflucan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10953 · Verify on the e-Formulary ↗ (DIN 00891819)
Source record
DIN 00891819: Diflucan
Raw flags: notABenefit=Y, sec3=Y
Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id PFI
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00891819
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10953Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891
Apo-Fluconazole · DIN 02237371 · $2.2891
Fluconazole · DIN 02517418 · $2.2891
Fluconazole · DIN 02534894 · $2.2891
Mylan-Fluconazole · DIN 02245293 · $2.2891
PMS-Fluconazole · DIN 02245644 · $2.2891
Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00891819
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered
Matched class: 08:12:04 Antifungals
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMPHOTERICIN B
Some products covered without a code (check the product listing): ITRACONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL
08:12:04 Antifungals
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered
Matched class: 84:04:08 Fungicides
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL
Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE
84:04:08 Fungicides
1 INDICATIONS
Treatment
DIFLUCAN (fluconazole) is indicated for the treatment of:
1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of
serious systemic candidal infections, including urinary tract infection, peritonitis, and
pneumonia.
2. Cryptococcal meningitis.
3. Prevention of the recurrence of cryptococcal meningitis in patients with acquired
immunodeficiency syndrome (AIDS).
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be
obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted
before the results of the cultures and other laboratory studies are known; however, once these results
become available, anti-infective therapy should be adjusted accordingly.
Prophylaxis
DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone
marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.
1.1 Pediatrics (<18 years of age)
Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DIFLUCAN in
pediatric patients ha…
https://pdf.hres.ca/dpd_pm/00085459.PDF
PM date: 2026-07-21
Source product: DIFLUCAN; DIN 02024152; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Act Fluconazole · DIN 02281260
Shortage status: discontinued (2024-12-20, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02281260
Apo-Fluconazole · DIN 02237370
Shortage status: shortage reported ended 2026-06-05 (report last updated 2026-06-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237370
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Diflucan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.